- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Femoden - low-dose monophasic oral combination estrogen-progestin contraceptive drug.
The contraceptive effect of Femodene is carried out through complementary mechanisms, the most important of which are the suppression of ovulation and changes in the properties of the cervical secretion, as a result of which it becomes impermeable to spermatozoa.
In women taking combined oral contraceptives, the menstrual cycle becomes more regular, painful menstruation is less common, the intensity of bleeding decreases, resulting in a reduced risk of iron deficiency anemia. In addition, there is evidence that the risk of developing endometrial cancer and ovarian cancer is reduced.
Absorption. After ingestion, gestodene is rapidly and completely absorbed, its maximum concentration in serum, equal to 3.5 ng / ml, is reached in approximately 1 hour. Bioavailability is approximately 99%.
Distribution. Gestodene binds to serum albumin and sex-derived steroid steroids (GLSS). In free form is only about 1.3% of the total serum concentration; about 69% are specifically associated with SHGPS. Induction of ethinyl estradiol synthesis of GSPS affects the binding of gestodene with whey protein.
Metabolism. Gestodene is almost completely metabolized. Serum clearance is approximately 0.8 ml / min / kg.
Removal. The content of gestodene in serum undergoes a two-phase reduction. The elimination half-life in the terminal phase is about 12 hours. In unchanged form, gestodene is not excreted, but only in the form of metabolites, which are excreted in urine and bile in a ratio of about 6: 4 with a half-life of about 24 hours.
Equilibrium concentration. The GSPG serum level affects the pharmacokinetics of gestodene. As a result of the daily intake of the drug, the level of the substance in the serum increases about 4 times during the second half of the treatment cycle.
Absorption. After ingestion, ethinyl estradiol is rapidly and completely absorbed. The maximum serum concentration of approximately 65 pg / ml is reached in 1-2 hours. During suction and the first passage through the liver, ethinyl estradiol is metabolized, with the result that its bioavailability by ingestion is on average about 45%.
Distribution. Ethinyl estradiol is almost completely (approximately 98%), although not specific, bound by albumin. Ethinyl estradiol induces the synthesis of SHBG. The apparent volume of distribution of ethinyl estradiol is 2.8-8.6 l / kg.
Metabolism. Ethinyl estradiol is subjected to presystemic conjugation, both in the mucous membrane of the small intestine and in the liver. The main metabolic pathway is aromatic hydroxylation. The rate of clearance from blood plasma is 2.3-7 ml / min / kg.
Removal. The decrease in the concentration of ethinyl estradiol in the blood serum is biphasic; the first phase is characterized by a half-life of about 1 hour, the second - 10-20 hours. Unchanged from the body is not displayed. Ethinyl estradiol metabolites are excreted in urine and bile in a ratio of 4: 6 with a half-life of about 24 hours.
Equilibrium concentration. Equilibrium concentration is reached in approximately one week.
Each dragee contains:
Active substance: 0.075 mg of gestodene and 0.03 mg of ethinyl estradiol.
Excipients: lactose monohydrate, corn starch, povidone 25000, sodium calcium edetate, magnesium stearate, sucrose, povidone 700000, polyethylene glycol (macrogol) 6000, calcium carbonate, talc, montano-glycolic wax.
No customer reviews for the moment.
- Brand name: Gavkamen
- Active ingredient: Camphor, Peppermint leaves oil / Levomenthol, Eucalyptus leaves
- Manufacturer: Tula pharmaceutical factory
- Country of Origin: Russia